Gilead COVID-19 drug may exceed $2 billion sales, analysts say

NEW YORK — At $4,500 for a round of treatment for Covid-19, remdesivir, Gilead Sciences Inc.'s new medicine, could be reasonably priced and still generate over $2 billion in revenue for the biotech, according to analysts at Piper Sandler. That's the ...

from Google Alert - Business https://ift.tt/2SCpTYN
NEW YORK — At $4,500 for a round of treatment for Covid-19, remdesivir, Gilead Sciences Inc.'s new medicine, could be reasonably priced and still generate over $2 billion in revenue for the biotech, according to analysts at Piper Sandler. That's the ... https://ift.tt/eA8V8J

Comments

Popular posts from this blog

Jobless Rate Drops

Electrolytic Fixed Power Capacitors Market Competitive intelligence & regional outlook 2020

USU project among finalists for $3 million solar energy tech prize